Can you take Bimekizumab with MTE-4 Concentrated?

The copper sulfate and manganese sulfate in MTE-4 Concentrated both have a moderate potential interaction with Biliary Obstruction.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

Bimekizumab has a moderate potential interaction with Depression.

Patients with a history of suicidal ideation or behavior reported a higher rate of new onset of suicidal ideation when treated with bimekizumab. Patients with a history of severe depression are also susceptible to suicidal ideation or behavior when treated with bimekizumab.

Bimekizumab has a moderate potential interaction with Infection.

Bimekizumab may increase the risk of infections, including tuberculosis (TB). Patients should be evaluated for any active infection before and during treatment with bimekizumab, and administration should be avoided if infection is detected. Evaluate patients for TB before treatment and avoid therapy in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.

Bimekizumab has a moderate potential interaction with Inflammatory Bowel Disease.

Cases of Inflammatory Bowel Disease (IBD) have been reported in patients treated with bimekizumab. Treatment with bimekizumab should be avoided in patients with active IBD.

Bimekizumab has a moderate potential interaction with Liver Disease.

Bimekizumab can cause increased levels of liver enzymes and bilirubin. Treatment with bimekizumab should be avoided in patients with acute liver disease or cirrhosis as they may be at increased risk for severe hepatic injury.

The copper sulfate and manganese sulfate in MTE-4 Concentrated both have a moderate potential interaction with Liver Disease.

The trace elements, copper and manganese, are excreted in the bile. Copper and manganese doses may need to be adjusted, reduced, or omitted in patients with liver disease or biliary obstruction.

The chromic chloride hexahydrate, copper sulfate, manganese sulfate and zinc sulfate in MTE-4 Concentrated all have a moderate potential interaction with Malabsorption Syndrome.

The trace metals manganese, chromium, copper, selenium, and zinc are absorbed in the GI tract from dietary sources and following administration of oral supplements. GI absorption may be decreased in patients with malabsorption syndromes. Therefore, larger dosages may be required when these supplements are given orally. Parenteral administration may be appropriate.

The manganese sulfate in MTE-4 Concentrated has a moderate potential interaction with Renal Dysfunction.

Manganese sulfate and manganese chloride preparations contain aluminum and may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum. Patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Caution is advised in patients with renal impairment, particularly in premature or neonates patients.

The chromic chloride hexahydrate and zinc sulfate in MTE-4 Concentrated both have a moderate potential interaction with Renal Dysfunction.

The trace metals, chromium and zinc, are excreted primarily in the urine. Selenium is partially excreted in the urine. Supplemental doses of these agents may need to be adjusted, reduced, or omitted in patients with renal dysfunction.